Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Acumen Pharmaceuticals, Inc. - Common Stock
(NQ:
ABOS
)
2.540
+0.070 (+2.83%)
Streaming Delayed Price
Updated: 1:59 PM EDT, May 8, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Acumen Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Acumen Pharmaceuticals to Participate in the Bank of America Securities 2026 Health Care Conference
May 07, 2026
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals to Report First Quarter Financial Results on May 12, 2026
May 05, 2026
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals Inc (NASDAQ:ABOS) Reports Narrower-Than-Expected Q4 Loss, Provides Key Clinical Update
↗
March 26, 2026
Via
Chartmill
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business Highlights
March 26, 2026
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Earnings Scheduled For November 12, 2025
↗
November 12, 2025
Via
Benzinga
Acumen Pharmaceuticals's Earnings: A Preview
↗
August 11, 2025
Via
Benzinga
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2025 Financial Results on March 26, 2026
March 19, 2026
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals Presents Studies on Enhanced Brain Delivery™, Biomarker Research, and Novel Antibodies at Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026
March 17, 2026
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio
March 16, 2026
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum
March 10, 2026
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals to Showcase Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026
March 03, 2026
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
These stocks have an unusual volume in today's session
↗
January 28, 2026
Via
Chartmill
Tuesday's after hours session: top gainers and losers
↗
January 27, 2026
Via
Chartmill
The market is filled with gapping stocks in Monday's session.
↗
January 26, 2026
Via
Chartmill
Acumen Pharmaceuticals Highlights Enhanced Brain Delivery™ Technology for Oligomer-Selective Antibodies and Recruitment Strategies for Phase 2 ALTITUDE-AD Clinical Trial at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
December 02, 2025
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals to Present on Recruitment Strategies for Phase 2 ALTITUDE-AD Trial and Enhanced Brain Delivery Technology at 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference
November 18, 2025
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals Announces First Participant Dosed in Phase 2 Open-Label Extension Study of Sabirnetug in People with Early Alzheimer’s Disease
November 17, 2025
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals Inc (NASDAQ:ABOS) Reports Q3 2025 Earnings, Beats EPS Estimates
↗
November 12, 2025
Acumen Pharmaceuticals posts better-than-expected Q3 2025 results, advancing its Alzheimer's treatment pipeline with cash into 2027.
Via
Chartmill
Topics
Earnings
Acumen Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Highlights
November 12, 2025
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Preview: Acumen Pharmaceuticals's Earnings
↗
November 11, 2025
Via
Benzinga
Acumen Pharmaceuticals Appoints George Golumbeski, Ph.D., as Chairman of its Board of Directors
November 10, 2025
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 12, 2025
November 05, 2025
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference
November 04, 2025
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
September 25, 2025
Gainers PepGen (NASDAQ: PEPG) stock rose 114.3% to $5.7 during Thursday's regular session. The market value of their outstanding shares is at $87.2 million.
Via
Benzinga
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences
August 26, 2025
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights
August 12, 2025
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025
August 05, 2025
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Acumen Pharmaceuticals Presents Studies Showing the Utility of a pTau217 Assay in Screening for a Phase 2 Alzheimer’s Disease Trial and Validates Sabirnetug Oligomer-Selectivity, at the Alzheimer’s Association International Conference (AAIC) 2025
July 28, 2025
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
Earnings Scheduled For August 12, 2025
↗
August 12, 2025
Via
Benzinga
Acumen Pharmaceuticals and JCR Pharmaceuticals Enter Strategic Collaboration, Option and License Agreement to Develop Enhanced Brain Delivery™ Therapy for Alzheimer’s Disease
July 15, 2025
From
Acumen Pharmaceuticals, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
